Qianqian Wang

Qianqian Wang

Auto-generated profile, based on publicly available information

Qianqian Wang

National-Local Joint Engineering Laboratory of Druggability and New Drugs Evaluation, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
YLYanping Liu
Yanping Liu
DGDawei Gao
Dawei Gao
XZXuwu Zhang
Xuwu Zhang
ZLZhiwei Liu
Zhiwei Liu
KDKun Dai
Kun Dai
LLLiyao Luo
Liyao Luo

26 June 2021 in World Journal of Clinical Cases
Verified
Journal Article
Open access
TYTeng-Fei Yin
Teng-Fei Yin
DZDongyan Zhao
Dongyan Zhao
YZYuan-Chen Zhou
Yuan-Chen Zhou
QWQian-Qian Wang
Qian-Qian Wang
SYShu-Kun Yao
Shu-Kun Yao
The high morbidity and mortality of colorectal cancer (CRC) have posed great threats to human health. Circular RNA (CircRNA) and microRNA (miRNA), acting as competing endogenous RNAs (ceRNAs), have been found to play vital roles in carcinogenesis. However, the biological function of ceRNAs in CRC pathogenesis and prognosis remains largely unexplored. To identify the CRC-specific circRNA-miRNA-mRNA regulatory network and uncover the subnetwork associated with its prognosis. CircRNAs, miRNAs and mRNAs differentially expressed (DE) in CRC tissues were selected by expression file analysis in the Gene Expression Omnibus (GEO) database, and the downstream target molecules of circRNAs and miRNAs were predicted. Then, the intersection of differentially expressed RNA molecules with the predicted targets was determined to obtain a ceRNA network. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were conducted to elucidate the possible mechanism of pathogenesis. A survival analysis using the gene profiles and clinical information in The Cancer Genome Atlas (TCGA) database was performed to identify the mRNAs associated with the clinical outcome of CRC patients and construct a prognostic subnetwork. We downloaded three datasets (GSE126095, GSE41655 and GSE41657) of large-scale CRC samples from the GEO database. There were 55 DEcircRNAs, 114 DEmiRNAs and 267 DEmRNAs in CRC tissues compared with normal tissues. After intersecting these molecules with predicted targets, 19 circRNAs, 13 miRNAs and 28 mRNAs were chosen to develop a circRNA-miRNA-mRNA network. GO and KEGG functional enrichment analyses indicated that the retinol metabolic process, leukocyte chemotaxis, extracellular matrix remodeling, endoplasmic reticulum stress, alcohol dehydrogenase activity, gastric acid secretion, nitrogen metabolism and NOD-like receptor signaling pathway might participate in the tumorigenesis of CRC. After verifying the identified mRNA effect in the TCGA database, we finally recognized 3 mRNAs (CA2, ITLN1 and LRRC19) that were significantly associated with the overall survival of CRC patients and constructed a ceRNA subnetwork including 5 circRNAs (hsa_circ_0080210, hsa_circ_0007158, hsa_circ_0000375, hsa_circ_0018909 and hsa_circ_0011536) and 3 miRNAs (hsa-miR-601, hsa-miR-671-5p and hsa-miR-765), which could contain innovative and noninvasive indicators for the early screening and prognostic prediction of CRC. We proposed a circRNA-miRNA-mRNA regulatory network closely associated with the progression and clinical outcome of CRC that might include promising biomarkers for carcinogenesis and therapeutic targets.

1 June 2020 in Diabetes
Verified
Journal Article
Closed access
SBSanjay K. Bajpai
Sanjay K. Bajpai
JCJanelle Cambron-Mellott
Janelle Cambron-Mellott
NRNedina K. Raibulet
Nedina K. Raibulet
EPEugenia Y. Peck
Eugenia Y. Peck
JPJiat Ling Poon
Jiat Ling Poon
KBKathleen Beusterien
Kathleen Beusterien
Objective: This study assessed preference, hesitation using, perceived ease of use, and feeling prepared and protected for nasal glucagon (NG) vs. autoinjector glucagon (AI) for rescue treatment of severe hypoglycemia (SH) among people with diabetes (PWDs), caregivers (CGs) and acquaintances (AQs). Methods: US PWDs (type 1 or 2, on insulin; n=405), CGs (n=313) and AQs (n=305) completed an online survey, after viewing a description of SH and graphics and descriptions of NG and AI (based on publicly available information at the time of study; prior to access to the final commercial device or their instructions for use). Respondents rated strength of preference for NG vs. AI on 16 attributes using direct elicitation (7-point scale; 1 = ‘very strongly prefer AI‘ and 7 = ‘very strongly prefer NG’, 4 = neutral); 4 items focused on overall preference, being less likely to hesitate using, perceived ease of use, and feeling prepared and protected, and 12 items were averaged to create a preference scale (e.g., size of device, less complicated). This measure was developed using established guidelines for instrument development, including qualitative research and assessment of the measure’s psychometric properties. One sample t-tests evaluated whether mean preference ratings differed from a neutral score. Results: Across PWDs, CGs, and AQs, NG was preferred over AI (all P<0.001 compared to neutral) on overall preference (4.5, 4.9, and 5.4, respectively), being less likely to hesitate using (4.8, 5.1, and 5.4, respectively), perceived ease of use (4.8, 5.1, and 5.4, respectively) and the preference scale (4.7, 5.0, and 5.3, respectively). CGs and AQs preferred NG vs. AI on feeling prepared and protected (4.6 and 4.8, respectively; both P<0.001 compared to neutral); PWDs were neutral (4.1, P=0.376). Conclusions: This study provides insights on PWDs’, CGs’ and AQs’ attitudes towards new glucagon devices, which may be considered when making product choices among the glucagon delivery systems. Disclosure: S.K. Bajpai: Employee; Self; Eli Lilly and Company. J. Cambron-Mellott: Other Relationship; Self; Eli Lilly and Company. N.K. Raibulet: Employee; Self; Eli Lilly and Company. E.Y. Peck: None. J. Poon: Employee; Self; Eli Lilly and Company. Q. Wang: Employee; Self; Eli Lilly and Company. B. Mitchell: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company. O. Will: Other Relationship; Self; Eli Lilly and Company. J. Babrowicz: Other Relationship; Self; Eli Lilly and Company. C.J. Child: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company. K. Beusterien: Other Relationship; Self; Eli Lilly and Company.

2 February 2026
Verified
Other
Open access
QWQianqian Wang
Qianqian Wang
LZLin Zhong
Lin Zhong
XWXiaojuan Wang
Xiaojuan Wang
ZZZhenhua Zhang
Zhenhua Zhang
GCGuodi Cai
Guodi Cai
JWJunjian Wang
Junjian Wang
Supplementary Table S4. The siRNA target sequences for RORC, HIF1A, VHL, EGLN1, EGLN2 and EGLN3 were listed as follows.

2 February 2026
Verified
Other
Open access
QWQianqian Wang
Qianqian Wang
LZLin Zhong
Lin Zhong
XWXiaojuan Wang
Xiaojuan Wang
ZZZhenhua Zhang
Zhenhua Zhang
GCGuodi Cai
Guodi Cai
JWJunjian Wang
Junjian Wang
Figure S5. Interaction between DNA binding domains of HIF-1α and RORγ prevents HIF-1α hydroxylation and promotes its nuclear translocation, related to Fig.5.

2 February 2026
Verified
Other
Open access
QWQianqian Wang
Qianqian Wang
LZLin Zhong
Lin Zhong
XWXiaojuan Wang
Xiaojuan Wang
ZZZhenhua Zhang
Zhenhua Zhang
GCGuodi Cai
Guodi Cai
JWJunjian Wang
Junjian Wang
Peritoneal metastasis (PM) is the most common and lethal form of metastasis in gastric cancer, highlighting an urgent need for treatment strategies. In this study, we identified retinoic acid receptor–related orphan receptor gamma (RORγ) as a key driver of PM in gastric cancer tumors. Integrative bioinformatics and IHC analyses revealed aberrant upregulation of RORγ in gastric cancer tumors, particularly in metastatic lesions. Functionally, elevated RORγ promoted gastric cancer cell adaptation to hypoxia and accelerated PM formation in vivo. The hypoxic microenvironment in gastric cancer stimulated RORγ expression, which in turn enhanced hypoxia-inducible factor 1α (HIF1α) stability, establishing a positive feedforward loop. Mechanistically, RORγ interacted with HIF1α and protected it from binding to proline hydroxylase domain 3 and von Hippel-Lindau, resulting in markedly decreased HIF1α hydroxylation and ubiquitylation and increased HIF1α accumulation, nuclear translocation, and transactivation. The RORγ–HIF1α complex bound to and activated target genes involved in the hypoxic response and epithelial-to-mesenchymal transition, thereby driving gastric cancer tumor growth and PM. Disruption of the RORγ–HIF1α interaction using RORγ antagonists markedly promoted HIF1α degradation and diminished its function. Importantly, in multiple gastric cancer xenograft models, RORγ inhibition effectively blocked tumor growth and PM while sensitizing tumors to chemotherapy. Thus, this study uncovers a mechanism of hypoxia-mediated metastasis through a RORγ–HIF1α reciprocal regulatory loop and offers a potential therapeutic option against PM in advanced cancer.Significance:RORγ drives peritoneal metastasis in gastric cancer and can be targeted to block metastatic progression, suggesting that RORγ inhibition could serve as a therapeutic strategy for advanced gastric cancer.